Technology evaluation: SB-485232, GlaxoSmithKline.
GlaxoSmithKline (formerly SmithKline Beecham), under license from Hayashibara, is developing SB-485232, a recombinant human interleukin-18 cancer immunotherapy for the potential treatment of immunologically sensitive cancers, including melanoma and renal cell cancer. The compound is currently undergoing phase II clinical trials.